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Background: OCT4 and BIRC5 are preferentially expressed in human cancer cells and mediate cancer cell survival
and tumor maintenance. However, the molecular mechanism that regulates OCT4 and BIRC5 expression is not well
characterized.
Methods: By manipulating OCT4 and BIRC5 expression in hepatocellular carcinoma (HCC) cell lines, the regulatory
mechanism of OCT4 on BIRC5 and CCND1 were investigated.
Results: Increasing or decreasing OCT4 expression could enhance or suppress BIRC5 expression, respectively, by
regulating the activity of BIRC5 promoter. Because there is no binding site for OCT4 within BIRC5 promoter, the
effect of OCT4 on BIRC5 promoter is indirect. An octamer motif for OCT4 in the CCND1 promoter has directly and
partly participated in the regulation of CCND1 promoter activity, suggesting that OCT4 also could upregulated the
expression of CCND1. Co-suppression of OCT4 and BIRC5 induced cancer cell apoptosis and cell cycle arrest,
thereby efficiently inhibiting the proliferative activity of cancer cells and suppressing the growth of HCC xenogrfts
in nude mice.
Conclusion: OCT4 can upregulate BIRC5 and CCND1 expression by increasing their promoter activity. These factors
collusively promotes HCC cell proliferation, and co-suppression of OCT4 and BIRC5 is potentially beneficial for HCC
treatment.
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Recurrence and metastasis of hepatocellular carcinoma
(HCC) depend on the persistent proliferative activity of
cancer cells. BIRC5, also called Survivin, has been shown
to play a pivotal role in cancers by influencing cell div-
ision and proliferation and by inhibiting apoptosis [1].
Many studies using clinical specimens have shown that
BIRC5 is invariably overexpressed in a majority of hu-
man cancers and is linked to poor patient prognosis but
is rarely expressed in normal tissues [2]. Based on the
abnormally high activation of BIRC5 during carcinogen-
esis in various types of cancers, treatment that targets* Correspondence: suchangqing@gmail.com
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reproduction in any medium, provided the orBIRC5 has been increasingly recognized as a promising
therapy for various cancers. However, when the anti-
BIRC5 agent is used alone, the long-term efficacy re-
mains uncertain and is variable for different types of
cancers; tumors have always relapsed and regrown in
later stages after treatment. Many factors are involved in
the regulation of BIRC5 expression and function, and
all of these factors influence the efficacy of BIRC5-tar-
geting strategies. We have found that P16 reactivation in
HCC cells down-regulates BIRC5 expression and limits
CDK4 import into nuclei, and then exhibits the effect
of cell cycle arrest and the induction of detachment-
induced apoptosis [3]. Another research group has re-
ported that the octamer-binding transcription factor 4
(OCT4) regulates BIRC5 expression, which was dramatically. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cells [4].
OCT4, a member of the POU-domain transcription
factor family, plays a pivotal role in the regulation and
maintenance of the cellular pluripotent state [5,6]. More
recently, the expression of OCT4 in human cancer cells
has been demonstrated [7-9]. OCT4 activates the tran-
scription of downstream target genes via its octamer
motif (50-ATGCAAAT-30) [10], and various genes have
been reported to have the OCT4 binding sites, inclu-
ding fibroblast growth factor 4 (FGF-4) [11]. Both global
chromatin immunoprecipitation assays and global ex-
pression profiling have been used to characterize the
gene regulatory network governed by OCT4, and a large
list of candidate target genes, whose regulatory sequen-
ces are recognized by OCT4, has been generated [12,13].
OCT4 also can bind to other similar sequence motifs
[13,14]. However, many downstream target genes do not
have OCT4 motifs but might still be valid candidates as
putative indirect targets of OCT4. The BIRC5 promoter
was reported to not have binding sites for OCT4, al-
though OCT4 knockdown in murine embryonic stem
cells has been shown to decrease the expression level of
BIRC5 protein, suggesting an indirect effect of OCT4 on
BIRC5 expression [4].
In this study, we investigated the regulatory mechan-
ism and significance of OCT4 on BIRC5 and CCND1
expression in HCC. Although the roles for BIRC5 and
OCT4 in cancers are well-recognized in a number of
previous studies, we gave the first evidence that OCT4
indirectly manipulates the expression and function of
BIRC5, and also directly upregulates the expression of
CCND1. These factors collude to promote cancer cell
proliferation and resist cancer cell apoptosis. This in-
novative finding provides new insight into the regulation
of OCT4 on CCND1 expression through a previously
unidentified mechanism and indicates a variety of novel
biological and prognostic markers, as well as potential
therapeutic targets, for cancer diagnosis and treatment.Methods
Vectors and adenoviruses
Vectors expressing the specific small hairpin RNA
(shRNA), including BIRC5-shRNA, OCT4-shRNA and
Dual-shRNA, were synthesized by and purchased from
Wuhan Genesil Biotechnology Co., Ltd. (Wuhan, China).
The 19-nt sense DNA of BIRC5-shRNA (50-GAAA
GTGCGCCGTGCCATC-30) targets base pairs 436–454
of the BIRC5 gene (HSU75285), and the 19-nt sense
DNA of OCT4-shRNA (50-CCCTCACTTCACTGCA
CTG-30) targets base pairs 1233–1253 of the OCT4 gene
(DQ486513.1). Both gene elements were controlled by
the U6 promoter. A mock control shRNA vector (Ctrl-shRNA, 50-GACTTCATAAGGCGCATGC-30) was con-
comitantly constructed.
Full-length OCT4 cDNA was cloned into pDC315
(Microbix Biosystems, Ontario, Canada) at the EcoRI
and SalI sites to generate pDC315-OCT4. Sequences of
the shRNA loop were digested from shRNA vectors and
then inserted into pDC315 at the BamHI and SalI
sites to obtain pDC315-shBIRC5, pDC315-shOCT4 and
pDual-shRNA. The plasmids pDC315-OCT4, pDC315-
shBIRC5, pDC315-shOCT4 and pDual-shRNA were
transfected into HEK293 cells (Microbix Biosystems,
Ontario, Canada) using the Lipofectamine 2000 reagent
(Invitrogen Corporation Shanghai Representative Office,
Shanghai, China) together with the type 5 adenovirus
packaging plasmid pBHGloxdelE13cre (Microbix Bio-
systems, Ontario, Canada) to generate a set of adenovi-
ruses named Ad5-OCT4, Ad5-shBIRC5, Ad5-shOCT4
and AdDual-shRNA.
Promoter-regulated reporter gene vectors
The luciferase plasmid pSRVN-Luc, in which luciferase
expression was under the control of the BIRC5 promoter
(nucleotides 1824–2800, GenBank U75285), was kindly
provided by Himanshu Garg (Center of Excellence for
Infectious Disease, Texas Tech University Health Scien-
ces Center, TX). The BIRC5 promoter was amplified
with the indicated primers (P1: 50-cgGCTAGCcatagaac
cagag-30; P2: 50-gaAGATCTgccgccgccgccacct-30) and
inserted into an EGFP plasmid at the NheI and BglII
sites to yield pSRVN-EGFP.
The wild type CCND1 promoter (wPro; nucleotides
2501–3178, GenBank Z29078.1) was amplified from
HepG2 genomic DNA with the indicated primers (P3:
50-cgGGATCCagattctttggccgtctgtc-30; P4: 50-cgGAATTC
AAGCTTggctggggctcttc ctg-30) and then inserted into
the luciferase plasmid at the BglII and HindIII sites to
generate pGL3wPro-Luc. The base pairs “ATTTGCAT”
in wPro from −252 to −245 were replaced by base
pairs “ATCTGTAT” and “ATTTGAAATGCAAAT (PORE
motif)” to construct the motif-mutated promoter (mPro)
and motif-enhanced promoter (ePro), respectively. The
mPro-controlled luciferase plasmid (pGL3mPro-Luc) and
the ePro-controlled luciferase plasmid (pGL3ePro-Luc)
were generated.
Animal experiments
Hep3B cells were subcutaneously injected into the right
flanks of BALB/c (nu/nu) mice (107 cells per mouse)
(Shanghai Experimental Animal Center, Chinese Acade-
my of Sciences, Shanghai, China) to establish xenograft
tumors. Ten weeks later, mice were separated random-
ly into 4 groups (Dual-shRNA, BIRC5-shRNA, OCT4-
shRNA and blank control groups) with 5 mice per group.
Mice in the virus-treated groups were given 5 viral
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total dosage of 109 pfu virus per mouse. Mice in the
control group were given the same volume of viral preser-
vation solution (10 mmol/L Tris–HCl pH 8.0, 2 mmol/L
MgCl2, 4% sucrose). Tumor size was measured regularly,
and the tumor volume was estimated with the formula
“a × b2 × 0.5”, in which a and b represent the maximal and
minimal diameters, respectively. The animal welfare
guidelines for the care and use of laboratory animals were
approved by the Animal Care Committee of Second Mili-
tary Medical University (No. SCXK2009-0003).
Statistical analysis
The experimental data were statistically analyzed using
the student's t test, and two-way analysis of variance
(ANOVA) according to the properties of the data. All
tests were performed using the PASW Statistics 18.0
software. P < 0.05 was considered statistically significant.
The detailed methods is available at Journal’s website as
Additional file 1: Supplementary Methods.
Results
BIRC5 expression was associated with OCT4 in HCC cells
To verify the regulation of OCT4 and BIRC5 expression
in HCC cells, a plasmid vector expressing BIRC5-specific
small hairpin RNA (BIRC5-shRNA) or OCT4-specific
small hairpin RNA (OCT4-shRNA) and an adenovirus
vector expressing OCT4 (Ad5-OCT4) were constructed
and used to manipulate the expression of BIRC5 and
OCT4 in HCC cells. Based on Western blotting results,
the parental HCC cells, including Hep3B, HepG2, PLC/
PRF5, SMMC-7721, BEL-7402, SK-Hep-1 and BEL-
7404, were all positive for BIRC5, although the expres-
sion levels were lower in SMMC-7721, BEL-7402 and
BEL-7404 cells than in Hep3B, HepG2, PLC/PRF5 and
SK-Hep-1 cells. Regarding OCT4 expression, Hep3B,
HepG2, PLC/PRF5 and SK-Hep-1 cells were positive and
BEL-7402 and BEL-7404 cells were negative (Figure 1A).
Using flow cytometric analysis, we analyzed CD133 ex-
pression of HCC cell lines. The results showed that the
percentages of CD133-positive cells were consistent with
OCT4 expression in these cell lines (Figure 1B).
Because Hep3B cells expressed both BIRC5 and
OCT4, and BEL-7404 cells expressed BIRC5 but not
OCT4, both cell lines were transfected with BIRC5-
shRNA and OCT4-shRNA vectors, and BEL-7404 cells
were infected with Ad5-OCT4. After transfection with
BIRC5-shRNA, BIRC5 expression was considerably down-
regulated in Hep3B and BEL-7404 cells, whereas OCT4
expression was not affected. However, after transfec-
tion with OCT4-shRNA, OCT4 expression was inhibi-
ted; BIRC5 was also clearly down-regulated even in the
OCT4-negative BEL-7404 cells. To further validate this
observation, BEL-7404 cells were infected with Ad5-OCT4, and the results demonstrated that adenovirus-
mediated overexpression of OCT4 leads to a significant
up-regulation of BIRC5 (Figure 1C).
The dynamic localization and expression levels of
BIRC5 and OCT4 were analyzed in HCC cells by im-
munofluorescent labeling. BIRC5 expression was obser-
ved in the cytoplasm of Hep3B parental cells and was
inhibited after transfection with BIRC5-shRNA. OCT4
expression was detected in the nuclei of Hep3B parental
cells and was inhibited after transfection with OCT4-
shRNA. OCT4-shRNA transfection consequently resul-
ted in the down-regulation of BIRC5 and also induced
cell apoptosis, as indicated by the occurrence of nuclear
condensation and apoptotic bodies (Figure 1D). In BEL-
7404 cells, BIRC5 expression was increased by adeno-
virus-mediated OCT4 expression in the cytoplasm and
nuclei (Figure 1E).
OCT4 upregulated BIRC5 expression by activating the
BIRC5 promoter
The expression of BIRC5 varied with changes in the ex-
pression of OCT4, suggesting that BIRC5 is under the
control of OCT4. To explore the superior-subordinate
relationship between BIRC5 and OCT4, the BIRC5 prox-
imal promoter was amplified (Figure 2A) and cloned
into luciferase reporter gene and enhanced green fluo-
rescent protein (EGFP) gene vectors, and the BIRC5
promoter activity was then measured in HCC cells.
Compared to the normal BJ cell line, the relative activity
of BIRC5 promoter in HCC cells was higher, particularly
in the Hep3B, PLC/PRF5 and HepG2 HCC cell lines.
OCT4-negative cells, such as BEL-7402 and BEL-7404,
also presented high BIRC5 promoter activity compared
to BJ cells (Figure 2B). After the inhibition of OCT4
expression with OCT4-shRNA, the relative BIRC5 pro-
moter activity in Hep3B cells was significantly suppres-
sed (p = 0.0099). Adenovirus-induced OCT4 expression
in BEL-7404 cells resulted in an increase in BIRC5 pro-
moter activity (P = 0.0199). Results using the EGFP vec-
tor were consistent with those using the luciferase vector
(Figure 2C).
OCT4 upregulated CCND1 expression by activating the
CCND1 promoter
OCT4 can control cell cycle by up-regulating target ge-
nes associated with cell cycle [10]. Therefore, we scree-
ned for OCT4 binding sites in the promoter regions of
these cell cycle regulators and found that the CCND1
proximal promoter contains an octamer motif at −252
to −245 (Figure 3A). After CCND1 expression in HCC
cells was confirmed by Western blotting, we cloned the
wild type, motif-mutated, and motif-enhanced CCND1
promoters and investigated OCT4 regulatory function
using the CCND1 promoter.
Figure 1 BIRC5 and OCT4 expression in HCC cell lines. (A) Cell lines were cultured in 6-well plates at a density of 105 cells/well for 48 h, and
then harvested for measuring expression of BIRC5 and OCT4 by Western blotting. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as the loading control, and densitometry analysis was performed to show BIRC5 and OCT4 expression levels normalized with GAPDH
density. (B) Cells were harvested, the CD133-positive cells were quantified by flow cytometry and showed in percentages of total cells counted;
*, P < 0.05; **, P < 0.01. (C) Cells were infected with Ad5-OCT4 at an MOI of 20 pfu/cell, or transfected with shRNA vectors at 20 μg/well. BIRC5 and
OCT4 expression was measured by Western blotting. Densitometry analysis was performed to show BIRC5 expression levels, normalized with
GAPDH density; *, P < 0.05; **, P < 0.01. (D, E) The parental, adenovirus-infected and shRNA-transfected HCC cells, including Hep3B (D) and
BEL-7404 (E), were cultured in Lab-Tek chamber at a density of 104 cells/well for 48 h, fixed in 4% formaldehyde for 30 min, and labeled by the
indicated fluorescent antibodies. DAPI was used to stain cellular nuclei, original magnification 400 × .
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Figure 2 BIRC5 promoter activity in HCC cells. (A) Scheme of binding sites for transcription factors in the BIRC5 proximal promoter region.
(B) Cell lines, including the indicated parental, adenovirus-infected and shRNA-transfected cells, were seeded on 24-well plates at a density of
5 × 104 cells/well and transfected with the BIRC5 promoter-driven luciferase plasmid pSRVN-Luc (200 ng/well). The relative activity of BIRC5
promoter in HCC cells was measured and shown in histograms; *, P < 0.05; **, P < 0.01. (C) Cells were seeded on 96-well plates at a density of
5 × 103 cells/well, transfected with the BIRC5 promoter-driven EGFP plasmid pSRVN-EGFP (2 μg/well), and observed under a fluorescent
microscope 48 h later, original magnification 200 × .
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Figure 3 CCND1 promoter activity in HCC cells. (A) The wild type CCND1 promoter (wPro) containing the transcription factor binding sites
was cloned from HepG2 DNA genome. From the wPro, the motif-mutated promoter (mPro) and motif-enhanced promoter (ePro) within −252 to
−245 were amplified and used to construct the CCND1 promoter-driven luciferase plasmids, pGL3wPro-Luc, pGL3mPro-Luc and pGL3ePro-Luc.
(B) CCND1 and OCT4 expression was detected by Western blotting in HCC cells. GAPDH was used as the loading control, and densitometry
analysis was performed to show CCND1 and OCT4 expression levels normalized with GAPDH density; **, P < 0.01. (C) The indicated parental,
adenovirus-infected and shRNA-transfected cells were seeded on 24-well plates at a density of 5 × 104 cells/well and transfected with the
plasmids pGL3wPro-Luc, pGL3mPro-Luc and pGL3ePro-Luc at 200 ng/well. The relative activity of CCND1 promoter in HCC cells was measured
and shown in histograms; *, P < 0.05; **, P < 0.01.
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CCND1 expression. Silencing of OCT4 expression by
OCT4-shRNA resulted in the down-regulation of CCND1
expression in Hep3B cells, whereas enhanced OCT4 ex-
pression by Ad5-OCT4 infection led to an up-regulation
of CCND1 expression in BEL-7404 cells (Figure 3B). The
relative CCND1 promoter activity was detected using the
luciferase reporter assay (Figure 3C). In OCT4-positive
Hep3B cells, the activity of mutated promoter (mPro) was
slightly lower compared to that of the wild type promoter
(wPro) (P = 0.0644), whereas the activity of the enhanced
promoter (ePro) with a PORE motif was significantly
higher (P = 0.0446). After the silencing of OCT4 ex-
pression, wPro or ePro activity was decreased relative
to the parental cells (wPro: P = 0.0192; ePro: P = 0.0075).
In OCT4-negative BEL-7404 cells, the three promotersFigure 4 Cell growth inhibition and cell apoptosis induced by co-sup
indicated shRNA-transfected Hep3B cells were cultured in 96-well plates at
measured by MTT assay at a wavelength of 570 nm with a reference wave
(B) The parental, adenovirus-infected and shRNA-transfected Hep3B cells at
cell apoptosis. Percentages of cell apoptosis were shown in histograms; *, Pconsistently maintained a similar level of activity. How-
ever, when OCT4 was re-expressed, wPro and ePro ac-
tivity was significantly increased (wPro: P = 0.0106; ePro:
P = 0.0167, compared with the parental cells).
Co-suppression of OCT4 and BIRC5 inhibits Hep3B cell
growth and induces cell apoptosis
To further explore the functions of OCT4 and BIRC5
in cancer cell proliferation, a dual-target shRNA vector
(Dual-shRNA) that targeted OCT4 and BIRC5 was cons-
tructed, and its inhibitory effect on HCC cells was com-
pared to that of the mono-target shRNA vectors. After
transfection with the shRNA vectors, cancer cell viability
was slightly lower with each of the vectors (Figure 4A).
The inhibitory effect of OCT4-shRNA on Hep3B cell
viability was stronger than that of BIRC5-shRNA, andpression of OCT4 and BIRC5 in HCC cells. (A) The parental and
a density of 5 × 103 cells/well for 48 and 72 h. Cell viability was
length of 655 nm and shown in histograms; *, P < 0.05; **, P < 0.01.
106 cells/ml were stained with PI and Annexin V-FITC for detection of
< 0.05; **, P < 0.01.
Figure 5 (See legend on next page.)
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Figure 5 Cell cycle arrest induced by co-suppression of OCT4 and BIRC5 in HCC cells. The parental, adenovirus-infected and shRNA-
transfected Hep3B cells at 106 cells/ml were stained with PI, and analyzed by flow cytometry. Data of cell cycle were shown in histograms;
*, P < 0.05; **, P < 0.01.
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among the shRNA vectors tested. By Annexin V-FITC/PI
labeling, the percentage of apoptotic cells (both Annexin
V-FITC-positive/PI-negative and Annexin V-FITC-po-
sitive/PI-positive) in the Dual-shRNA-transfected po-
pulation was shown higher than the percentage of the
other two shRNA vector-transfected cell populations
(Figure 4B).
Co-suppression of OCT4 and BIRC5 induces Hep3B cell
cycle arrest
The parental and shRNA-transfected Hep3B cells were
then examined by flow cytometry using propidium io-
dide (PI) staining to identify phases of cell cycle arrest.
Compared with the parental cells, OCT4-shRNA trans-
fection resulted in a G1-phase arrest (P = 0.0193) and
G2-phase decrease (P = 0.0067); BIRC5-shRNA transfec-
tion resulted in a G2-phase arrest (P = 0.0129), and
Dual-shRNA transfection resulted in a distinct G1-phase
arrest (P = 0.0072) and S-phase decrease (P = 0.0024;
Figure 5).
Simultaneously silencing of OCT4 and BIRC5 exhibits
strong antitumor potency against HCC xenograft tumors
in nude mice
Hep3B xenograft tumors were established in nude mice
and infected with adenoviruses carrying OCT4-shRNA
or/and BIRC5-shRNA. Compared with the control group,
adenovirus with Dual-shRNA exerted the strongest in-
hibitory effect on tumor growth because the tumor inhi-
bitory rate was 67.59% (P = 0.0001) compared to 44.54%
(P = 0.0020) and 25.25% (P = 0.0418) in the OCT4-shRNA
and BIRC5-shRNA groups, respectively (Figure 6A). After
completing the treatments, tumors in the BIRC5-shRNA
group gradually regrew, but those in the OCT4-shRNA
group showed a longer-lasting growth-inhibitory effect.
Adenovirus with Dual-shRNA exhibited the greatest anti-
tumor potency (P = 0.0358 for the OCT4-shRNA group,
P = 0.0025 for the BIRC5-shRNA group, versus the Dual-
shRNA group). After the observation period, the mice
were killed, and the tumors were removed. The tumor
weights also indicated that the Dual-shRNA group had
the greatest antitumor efficacy (Figure 6B).
Paraffin-embedded tumor sections were examined by
immunohistochemistry and terminal deoxynucleotidyl
transferase-mediated dUTP nick end labelling (TUNEL).
In the blank control group, cancer cells were positive for
OCT4 and BIRC5 expression, and few tumor cells were
positive for TUNEL staining. However, in the BIRC5-shRNA group, BIRC5 expression was down-regulated and
the apoptotic cell percentage was increased. When OCT4
expression was down-regulated by OCT4-shRNA in tu-
mor cells, BIRC5 expression was also suppressed ac-
companied by an increase in the percentage of apoptotic
cells. The Dual-shRNA simultaneously silenced OCT4
and BIRC5 expression and resulted in a significant in-
crease in apoptotic cells in Hep3B xenograft tumors
(Figure 6C).
Discussion
As a member of the inhibitors of apoptosis protein
(IAPs) family, BIRC5 is preferentially expressed in hu-
man cancer cells and has multiple functions, inclu-
ding the inhibition of cell apoptosis [1], control of the
cell cycle [15,16], promotion of tumor angiogenesis
[17,18], resistance to chemotherapy or radiotherapy [19],
acceleration of metastasis and recurrence [20,21], and
regulation of cancer cell autophagy [22], all of which fa-
vour cancer cell survival and tumor maintenance. There-
fore, multiple strategies have been employed to target
BIRC5 for cancer therapy by silencing BIRC5 expression
with small interfering RNA [23] or antisense oligonucleo-
tides [24], inhibiting the BIRC5 promoter activity with
small-molecule antagonists [25], and interfering BIRC5
function with dominant-negative mutant forms of the pro-
tein [26]. Some of these strategies are being applied in
clinical trials at various phases, and the initial results are
promising when combined with other treatments, such as
chemotherapy or radiotherapy [16,27]. Although certain
strategies for cancer therapy targeting BIRC5 have shown
a varied extent of antitumor efficacy, the potential benefit
of single anti-BIRC5 treatment in different types of can-
cers is uncertain. Although the down-regulation of BIRC5
expression by anti-BIRC5 agents can inhibit the growth of
cancer, tumors consistently obtain growth capabilities in
later stages, demonstrating that this treatment approach
remains poorly characterized and requires further study.
BIRC5 expression is precisely regulated at transcrip-
tional and post-translational levels. The signal transducer
and activator of transcription 3 (Stat-3), β-catenin-acti-
vated T-cell factor (TCF) transcription factor, hypoxia-
inducible factor-1 alpha (HIF-1α) and Sp1 transcription
factor promote BIRC5 expression by increasing BIRC5
promoter activity [28-31]. Sp1-mediated BIRC5 expression
can be suppressed by p53 [32]. The stability of BIRC5
protein represents another potential method of regu-
lating BIRC5 function. BIRC5 protein is phosphorylated at
Thr34 by cdc2 kinase, which prevents BIRC5 proteosome-
Figure 6 Antitumour efficacy of OCT4 and BIRC5 co-suppression in mouse xenograft models. (A) Hep3B cells were injected into BALB/c
(nu/nu) mice for establishing xenograft tumours. Adenoviruses carrying Dual-shRNA, BIRC5-shRNA, OCT4-shRNA were used to treat tumours by
intratumoural injections with a total dosage of 109 pfu viruses per mouse, and the tumour volume was measured every week. (B) Observation
was ended (day 39 after treatment) when the tumours were over 2,500 mm3. Mice were killed, tumours were removed and weighed; *, P < 0.05,
n = 5; **, P < 0.01, n = 5. (C) The paraffin-embedded consecutive sections of tumours were detected for OCT4 and BIRC5 expression by
immunohistochemistry and for counting apoptotic cells by TUNEL, original magnification 200 × .
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was reported to have a regulatory effect on BIRC5 expres-
sion [4].
OCT4 belongs to the family of POU-domain transcrip-
tion factors, which are involved in the regulation of cell
growth and differentiation in a variety of tissues [11,34].
Many studies have shown that OCT4 expression is res-
tricted to germline and pregastrulation embryos and also
to embryonal carcinomas and testicular germ cell tu-
mors [7], but not expressed in mature somatic cells. Fur-
ther evidence has shown that some cancer cells, such as
breast, bladder, prostate, liver, head and neck squamouscell cancer and non-small cell lung cancers, are positive
for OCT4 expression [7-9,35-39]. Therefore, OCT4 acts
as a multifunctional factor not only in stem cells but also
in many cancers, and the expression of OCT4 causes
more malignant histological phenotypes, including rapid
progression, great metastasis, and short cancer-related
survival. However, one study unexpectedly found that
adult human peripheral blood mononuclear cells, which
are genetically stable and mainly terminally differen-
tiated cells with a limited lifespan, express OCT4; this
finding challenges the paradigm of OCT4 as a marker
of pure stem cells and provides novel insight into the
Cao et al. BMC Cancer 2013, 13:82 Page 11 of 13
http://www.biomedcentral.com/1471-2407/13/82role of OCT4 in fully differentiated cells [11]. OCT4
functions by directly or indirectly activating a series of
downstream target genes. By characterizing the genes in
OCT4-mediated regulatory networks, it has been found
that many candidate target genes that are directly regu-
lated by OCT4 have an OCT4-binding octamer motif
[10]. However, a large number of target genes, such as
BIRC5 [4], have no OCT4 motifs and might be indirectly
regulated by OCT4. Therefore, transcriptional regulation
of target genes by OCT4 is very complicated, and it
is necessary to understand the key gene network that
maintains cell pluripotency in embryo development and
governs cell differentiation and proliferation in cancer
progression.
To clarify the relationship between OCT4 and BIRC5
in HCC, we first analyzed the OCT4 and BIRC5 expres-
sion levels in HCC cell lines, including Hep3B, HepG2,
PLC/PRF5, SMMC-7721, BEL-7402 and BEL-7404. All
cell lines were positive for BIRC5 expression, although
only the Hep3B, HepG2 and PLC/PRF5 cells were posi-
tive for OCT4 expression; SMMC-7721 cells were
weakly positive for OCT4 expression. OCT4 and BIRC5
expression was also investigated by immunohistochemis-
try in 49 pairs of cancer and liver tissues taken from
HCC patients. They were overexpressed in HCC com-
pared with the corresponding liver tissues (Additional
file 2: Table S1). BIRC5 immunostaining was mainly lo-
calized in cancer cell cytoplasm and nuclei, and OCT4
expression was localized in cancer cell nuclei (Additional
file 3: Figure S1).
We found that the expression levels of OCT4 in HCC
cell lines were consistent with the percentages of
CD133-positive cells, suggesting that OCT4 expression
might be related to CD133 expression. By manipulating
the expression of OCT4 and BIRC5, we found that
BIRC5 expression silencing did not influence OCT4 ex-
pression in Hep3B and BEL-7404 cells. However, down-
regulation of OCT4 expression inhibited BIRC5 expres-
sion, even in the OCT4-negative BEL-7404 cells, and in-
creasing OCT4 expression by infection with adenovirus
carrying the OCT4 gene in BEL-7404 cells up-regulated
BIRC5 expression. In exploring the superior-subordinate
relationship between BIRC5 and OCT4, we found that
the relative activity of the BIRC5 promoter in HCC cells
was controlled by OCT4. These results seemingly
demonstrated that BIRC5 is a downstream target gene
of OCT4.
Functional binding sites for the transcription factors
SP1, KLF5, HIF-1α, Rb/E2F, TCF4 and Egr1 have been
found in the BIRC5 gene promoter, suggesting that these
factors regulate BIRC5 gene expression [40]. However,
a binding site for OCT4 is not found in the BIRC5 pro-
moter region, suggesting that OCT4 may indirectly re-
gulate BIRC5 expression [13,40]. In addition to the Rbsuppressor and E2F activators (i.e., E2F1, E2F2 and E2F3)
that bind directly to the BIRC5 promoter and regulate
BIRC5 transcription [41], the regulatory proteins CDK4,
SKP2, Rad51, BRCA2, E2F-DP1, CCND1, Stat3, Rb and
p21 can activate the SP1 promoter [42], which then in-
directly leads to an increase in BIRC5 expression. These
factors are all involved in cell cycle regulation. In ad-
dition, OCT4 modulates the cell cycle by up-regulating
CDKN1B, CDKN1C, CDK6 and MAPK4 [10]. Coinci-
dentally, by screening the binding sites in the promoter
regions of these cell cycle regulators, we found an octamer
motif for OCT4 at −252 to −245 in the CCND1 proximal
promoter. Further studies have confirmed that CCND1
expression and promoter activity is strictly correlated with
OCT4 expression levels in OCT4-positive Hep3B cells.
When the OCT4 motif in the CCND1 promoter was
mutated or modified with a PORE motif that could bind
two OCT4 molecules, the promoter activity was suppres-
sed or enhanced, respectively. We also observed high
CCND1 promoter activity in OCT4-negative BEL-7404
cells. These results suggested that the OCT4 motif might
participate in the regulation of CCND1 promoter activity,
and that there are other factors that regulate CCND1 pro-
moter activity in HCC cells.
In the in vitro experiments, silencing of BIRC5 expres-
sion effectively induced apoptosis and cell cycle arrest in
HCC cells, thereby inhibiting cancer cell proliferation
and decreasing cancer cell viability. Co-suppression of
OCT4 and BIRC5 further enhanced the inhibitory effect
on cancer cell proliferation. In the in vivo experiments,
BIRC5-shRNA expression inhibited the growth of HCC
xenograft tumors by inducing cell apoptosis, although
tumor growth was restored in the late stage after the
adenovirus injections ceased. The Dual-shRNA that tar-
geted both OCT4 and BIRC5 inhibited tumor growth
with great efficiency for a long period of time. These
results showed that OCT4 and BIRC5 collusively educe
cell proliferation. Clinical follow-up information also
demonstrated that the HCC patients who showed co-
expression of OCT4 and BIRC5 in cancer tissues had
poorer disease-free survival (DFS) and overall survival
(OS) than patients who were negative for both OCT4
and BIRC5 (Additional file 4: Figure S2).
Conclusions
This study demonstrated that OCT4 is an upstream
gene that indirectly upregulates BIRC5 expression, and
directly upregulates CCND1 expression. These factors
collude to promote the proliferation of cancer cells and
contribute to the poor prognosis of HCC patients. The
innovative finding provides new insight into the regu-
lation of OCT4-BIRC5 or OCT4-CCND1 signaling in
HCC, which may be helpful for cancer diagnosis and
treatment.
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Additional file 1: Materials and methods.
Additional file 2: Table S1. OCT4 and BIRC5 expression related to HCC
clinicopathological features.
Additional file 3: Figure S1. OCT4 and BIRC5 overexpression in clinical
hepatocellular carcinoma (HCC) specimens. (A) Forty-nine pairs of cancer
tissues and liver tissues were taken from clinical HCC patients. All patients
underwent hepatectomy at the Eastern Hepatobiliary Surgery Hospital
(Shanghai, China) between September 25, 2007, and September 30, 2009.
The study patients were confirmed to have no distant metastases,
detectable ascites, or chemotherapy and radiotherapy before surgery. The
resected lesions were diagnosed pathologically as HCC after surgery.
Paraffin-embedded consecutive sections were subjected to
immunohistochemical examination for BIRC5 and OCT4 expression using
the UltraSensitive Streptavidin Proxidase Kit (Fuzhou Maixin
Biotechnology Development Co., Fuzhou, China), original magnification
200×. (B) OCT4 and BIRC5 expression levels were scored according to the
percentages of positive cells counted within 5 high-power fields, positive
cell percentages from <10% to <100% were defined as score 1 to 9, all
cells that were negative were scored as zero. Patient with 2 or more than
score 2 was qualified as positive case. The clinical study was performed
after obtaining the informed consent from every patient and did not
show the patients’ names.
Additional file 4: Figure S2. Correlation of OCT4 and BIRC5 to
prognosis of HCC patients. (A) Follow-up for HCC patients started on the
operation date and ended on August 1, 2010. The median duration of
follow-up was 12.67 months (ranging from 1.6 to 34.2 months). During
the follow-up period, patients were monitored for tumor recurrence by
examination of serum AFP, abdominal ultrasound, chest radiography,
computed tomography and/or magnetic resonance imaging; finally
patients were also subjected to imaging diagnosis to find recurrent
tumors. The disease-free survival (DFS) was defined as the time period
from the follow-up start date to the date of tumor recurrence (for the
patients with tumor recurrence) or the follow-up end date (for the
patients without tumor recurrence), and the overall survival (OS) was
defined as the time period from the start date of follow-up to the date
of death or the end date of follow-up. Survival curves were calculated by
the Kaplan-Meier method, and the significant difference among the three
groups was compared using log-rank test. (B) Every two groups were
compared and shown in Kaplan-Meier curves.
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